Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.

Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Original Publication: London : BioMed Central, [2001-

Diagnostic Self Evaluation* ; Surveys and Questionnaires*/standards; Antineoplastic Agents/*adverse effects ; Peripheral Nervous System Diseases/*chemically induced ; Peripheral Nervous System Diseases/*therapy ; Self Care/*methods; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Neurotoxicity Syndromes/psychology ; Neurotoxicity Syndromes/therapy ; Peripheral Nervous System Diseases/psychology ; Quality of Life/psychology ; Self Care/psychology ; Self Care/standards ; Treatment Outcome ; Young Adult

Background: Impaired physical function due to chemotherapy-induced peripheral neuropathy (CIPN) symptoms may lead to diminished quality of life. However, even with the knowledge of the effects of CIPN on physical function, clinicians infrequently assess and manage CIPN. Interventions that prioritize the early identification of CIPN to provide prompt treatment may reduce the impact of CIPN on physical function. The purpose of this paper is to compare self-reported physical function in individuals receiving neurotoxic chemotherapy between Electronic Symptom Assessment-Cancer (ESRA-C) intervention group (e.g., opportunity for symptom screening, self-care recommendations, communication coaching, and symptom tracking) and control group participants (i.e., electronic assessment alone). Secondary outcomes include pain intensity, sensory/motor CIPN, depression, fatigue, and insomnia.
Methods: The data used in this paper are a subset of a randomized controlled trial that examined the impact of the ESRA-C intervention on symptom distress in individuals receiving cancer treatment. Since the interest in this analysis is on the effects of neurotoxic chemotherapy on physical function, subjects were included if they received platinum and/or taxane-based chemotherapy and completed the baseline and end-of-treatment measures. Participants completed standardized questionnaires of physical function, CIPN, fatigue, depression, pain intensity, and insomnia prior to treatment, 3-6 weeks after treatment initiation, and after the completion of treatment. Changes in mean scores are compared between groups using linear mixed models adjusting for age.
Results: Intervention group participants reported significantly less reduction in physical functioning (baseline: 87.4/100; end-of-treatment: 84.5/100) relative to the control (baseline: 90.2/100; end-of-treatment: 81.8/100) (p = 0.011). For secondary measures, significantly less depression (p = 0.005) was observed in the intervention group as compared to the control, but otherwise, there were no between-group differences. Among participants who received high cumulative doses of neurotoxic chemotherapy, the intervention group reported significantly less severe sensory (p = 0.007) and motor CIPN (p = 0.039) relative to the control.
Conclusion: Use of the ESRA-C intervention led to less reduction in physical function in comparison to the control in individuals receiving neurotoxic chemotherapy. Further research is needed to confirm our findings and to identify how electronic symptom assessment technology may mediate physical function preservation.
Trial Registration: ClinicalTrials.Gov NCT00852852 . Registered 27 February 2009.

Erratum in: BMC Cancer. 2019 May 13;19(1):438. (PMID: 31084600)

Pain Med. 2007 Apr;8(3):223-34. (PMID: 17371409)
J Gen Intern Med. 2001 Sep;16(9):606-13. (PMID: 11556941)
JAMA Neurol. 2016 Jul 1;73(7):860-6. (PMID: 27183099)
Comput Inform Nurs. 2017 Apr;35(4):201-211. (PMID: 28002115)
JAMA. 1999 Nov 10;282(18):1737-44. (PMID: 10568646)
ANS Adv Nurs Sci. 1997 Mar;19(3):14-27. (PMID: 9055027)
Breast Cancer Res Treat. 2013 Nov;142(1):109-18. (PMID: 24132874)
J Clin Oncol. 2017 Aug 10;35(23):2604-2612. (PMID: 28586243)
J Med Internet Res. 2015 Jun 03;17(6):e136. (PMID: 26041682)
J Clin Oncol. 2014 Jan 20;32(3):199-205. (PMID: 24344222)
CA Cancer J Clin. 2017 Jan;67(1):7-30. (PMID: 28055103)
J Natl Compr Canc Netw. 2009 Sep;7 Suppl 5:S1-S26; quiz S27-8. (PMID: 19755042)
Med Care. 2004 Dec;42(12):1194-201. (PMID: 15550799)
Psychol Methods. 2010 Dec;15(4):309-34. (PMID: 20954780)
J Natl Cancer Inst. 2017 Jan 24;109(4):. (PMID: 28119347)
Acta Oncol. 2015 May;54(5):587-91. (PMID: 25751757)
Gerontology. 2016;62(5):553-63. (PMID: 26678611)
Clin J Oncol Nurs. 2013 Apr;17(2):138-44. (PMID: 23538249)
Eur J Cancer. 2000 Sep;36(14):1796-807. (PMID: 10974628)
Semin Oncol Nurs. 1987 Nov;3(4):248-56. (PMID: 3423446)
Comput Inform Nurs. 2016 Jul;34(7):322-9. (PMID: 27116414)
JAMA. 2013 Apr 3;309(13):1359-67. (PMID: 23549581)
Health Qual Life Outcomes. 2016 Jun 07;14:87. (PMID: 27267486)
Chemother Res Pract. 2012;2012:913848. (PMID: 22482054)
J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. (PMID: 8433390)
Front Pharmacol. 2017 Feb 24;8:86. (PMID: 28286483)
Ann Oncol. 2011 Sep;22(9):2107-12. (PMID: 21324954)
Qual Life Res. 2013 Dec;22(10):2787-99. (PMID: 23543373)
Support Care Cancer. 2018 Apr;26(4):1019-1028. (PMID: 29243164)
Clin Breast Cancer. 2007 Apr;7(7):550-4. (PMID: 17509163)
Eur J Cancer. 1995 Dec;31A(13-14):2260-3. (PMID: 8652253)
J Natl Cancer Inst. 2016 Oct 28;109(2):. (PMID: 27794123)
Annu Rev Clin Psychol. 2011;7:411-34. (PMID: 21128783)
Support Care Cancer. 2018 Feb;26(2):615-624. (PMID: 28963591)
Ann Oncol. 2014 Jan;25(1):257-64. (PMID: 24256846)
Oncol Nurs Forum. 2014 Nov 1;41(6):669-79. (PMID: 25355022)
Neuro Oncol. 2012 Sep;14 Suppl 4:iv45-54. (PMID: 23095830)
Pain. 2005 Jan;113(1-2):9-19. (PMID: 15621359)
J Clin Oncol. 2014 Jun 20;32(18):1941-67. (PMID: 24733808)
Eur J Oncol Nurs. 2016 Apr;21:215-22. (PMID: 26645947)
Breast Cancer Res Treat. 2017 Jul;164(1):69-77. (PMID: 28374323)
Clin J Oncol Nurs. 2018 Oct 1;22(5):E134-E140. (PMID: 30239516)
Support Care Cancer. 2016 Nov;24(11):4779-89. (PMID: 27470258)
Curr Oncol Rep. 2017 Aug 18;19(10):67. (PMID: 28822063)
Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77. (PMID: 21908200)
Epidemiol Rev. 2017 Jan 1;39(1):59-70. (PMID: 28453627)
J Community Support Oncol. 2014 Nov;12(11):401-6. (PMID: 25856013)
Front Neurosci. 2017 Aug 31;11:481. (PMID: 28912674)
Qual Life Res. 2017 Oct;26(10):2763-2772. (PMID: 28664460)
J Pain Symptom Manage. 2012 Dec;44(6):810-22. (PMID: 22771125)
Pain. 2014 Dec;155(12):2461-70. (PMID: 25261162)
Eur J Cancer. 2005 May;41(8):1135-9. (PMID: 15911236)
J Cancer Educ. 2018 Oct;33(5):1027-1035. (PMID: 28265863)
Support Care Cancer. 2018 May;26(5):1607-1615. (PMID: 29204710)
J Pain Symptom Manage. 2011 Jun;41(6):1073-93. (PMID: 21621130)
J Pain Symptom Manage. 2016 Jan;51(1):88-98. (PMID: 26300025)
J Pain. 2018 Apr;19(4):382-394. (PMID: 29229430)

R01 NR008726 United States NR NINR NIH HHS; UL1 TR001102 United States TR NCATS NIH HHS; R01 NR008726 National Institute of Nursing Research

Keywords: Cancer symptom management; Chemotherapy-induced peripheral neuropathy; Electronic symptom assessment; Peripheral nervous system diseases/chemically-induced; Technology assessment

ClinicalTrials.gov NCT00852852

0 (Antineoplastic Agents)

Date Created: 20181206 Date Completed: 20190325 Latest Revision: 20190518

20240829

PMC6278100

10.1186/s12885-018-5093-z

30514351